📊 ZYME Key Takeaways
Is Zymeworks Inc. (ZYME) a Good Investment?
Early-stage pharmaceutical company with a fortress balance sheet ($244.3M cash, zero debt) but extreme cash burn (-$45.7M annually) and minimal revenue ($2.4M); while balance sheet strength provides multi-year runway and 38.9% revenue growth shows improvement, the company remains far from profitability with -1834% net margins and no clear path to sustainable operations without major clinical breakthroughs.
Zymeworks Inc. Key Strengths (ZYME)
- Fortress balance sheet with $244.3M cash and zero long-term debt, providing substantial financial flexibility and ~5+ year runway at current burn rate
- Excellent liquidity position (10.82x current ratio) mitigates near-term financial distress risk despite ongoing losses
- Revenue growth of 38.9% YoY and improving unit economics (EPS loss reduced 33.3% YoY) suggest early commercialization momentum
ZYME Stock Risks: Zymeworks Inc. Investment Risks
- Massive operating losses (-$47.1M) on minimal revenue ($2.4M) with -1834% net margin; business model is fundamentally unprofitable at current scale
- Significant operating cash burn rate (-$45.7M annually) is unsustainable without achievement of major pharmaceutical milestone or partnership event
- Pharmaceutical/biotech regulatory risk with uncertain pipeline success; no visibility into clinical trial outcomes or commercialization timeline from financials alone
Key Metrics to Watch
- Quarterly operating cash burn trend and timeline to cash flow breakeven
- Revenue trajectory and composition (recurring vs. milestone/license revenue)
- Pipeline clinical trial results, regulatory approvals, and partnership announcements
- R&D and G&A expense trends relative to revenue growth
- Cash balance depletion rate and potential for equity raise dilution
Zymeworks Inc. (ZYME) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 10.82x current ratio provides a solid financial cushion.
ZYME Profit Margin, ROE & Profitability Analysis
ZYME vs Healthcare Sector: How Zymeworks Inc. Compares
How Zymeworks Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Zymeworks Inc. Stock Overvalued? ZYME Valuation Analysis 2026
Based on fundamental analysis, Zymeworks Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Zymeworks Inc. Balance Sheet: ZYME Debt, Cash & Liquidity
ZYME Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Zymeworks Inc.'s revenue has declined by 74% over the 5-year period, indicating business contraction. The most recent EPS of $-1.72 indicates the company is currently unprofitable.
ZYME Revenue Growth, EPS Growth & YoY Performance
ZYME Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $2.4M | -$22.6M | $-0.30 |
| Q3 2025 | $16.0M | $2.3M | $-0.26 |
| Q2 2025 | $19.2M | $2.3M | $0.03 |
| Q1 2025 | $10.0M | -$22.6M | $-0.30 |
| Q3 2024 | $16.0M | -$24.4M | $-0.39 |
| Q2 2024 | $7.0M | -$24.4M | $-0.49 |
| Q1 2024 | $10.0M | -$24.4M | $-0.37 |
| Q3 2023 | $2.6M | -$24.4M | $-0.41 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Zymeworks Inc. Dividends, Buybacks & Capital Allocation
ZYME SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Zymeworks Inc. (CIK: 0001937653)
📋 Recent SEC Filings
❓ Frequently Asked Questions about ZYME
What is the AI rating for ZYME?
Zymeworks Inc. (ZYME) has an AI grade of C with 68% confidence, based on fundamental analysis of SEC EDGAR filings.
What are ZYME's key strengths?
Claude: Fortress balance sheet with $244.3M cash and zero long-term debt, providing substantial financial flexibility and ~5+ year runway at current burn rate. Excellent liquidity position (10.82x current ratio) mitigates near-term financial distress risk despite ongoing losses.
What are the risks of investing in ZYME?
Claude: Massive operating losses (-$47.1M) on minimal revenue ($2.4M) with -1834% net margin; business model is fundamentally unprofitable at current scale. Significant operating cash burn rate (-$45.7M annually) is unsustainable without achievement of major pharmaceutical milestone or partnership event.
What is ZYME's revenue and growth?
Zymeworks Inc. reported revenue of $2.4M.
Does ZYME pay dividends?
Zymeworks Inc. does not currently pay dividends.
Where can I find ZYME SEC filings?
Official SEC filings for Zymeworks Inc. (CIK: 0001937653) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is ZYME's EPS?
Zymeworks Inc. has a diluted EPS of $-0.59.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is ZYME's fundamental grade?
Based on our AI fundamental analysis in June 2026, Zymeworks Inc. has a C grade with 68% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is ZYME stock overvalued or undervalued?
Valuation metrics for ZYME: ROE of -27.0% (sector avg: 15%), net margin of -1,834.0% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is ZYME's AI grade for 2026?
Our dual AI analysis gives Zymeworks Inc. a combined C grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is ZYME's free cash flow?
Zymeworks Inc.'s operating cash flow is $-45.7M, with capital expenditures of $216.0K. FCF margin is -1,907.6%.
How does ZYME compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -1,834.0% (avg: 12%), ROE -27.0% (avg: 15%), current ratio 10.82 (avg: 2).